NO331477B1 - Etanolat pseudopolymorfe former av en HIV-proteaseinhibitor, fremgangsmate ved fremstilling derav samt anvendelse derav - Google Patents

Etanolat pseudopolymorfe former av en HIV-proteaseinhibitor, fremgangsmate ved fremstilling derav samt anvendelse derav Download PDF

Info

Publication number: NO331477B1
Authority: NO; Norway
Prior art keywords: compound; ethanol; formula; pseudopolymorph; ethanolate
Prior art date: 2002-05-16

Application number

NO20045409A

Other languages

English (en)

Norwegian (no)

Other versions

NO20045409L (no

Inventor

Daniel Joseph Christiaan Thone

Hans Wim Pieter Vermeersch

Luc Donne Marie-Louise Janssens

Piet Tom Bert Paul Wigerinck

Original Assignee

Tibotec Pharm Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-16

Filing date

2004-12-10

Publication date

2012-01-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO331477(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-12-10 Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd

2004-12-10 Publication of NO20045409L publication Critical patent/NO20045409L/no

2012-01-16 Publication of NO331477B1 publication Critical patent/NO331477B1/no

Links

238000000034 method Methods 0.000 title claims abstract description 41
238000002360 preparation method Methods 0.000 title claims abstract description 17
HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 title claims description 15
239000004030 hiv protease inhibitor Substances 0.000 title description 2
229940122440 HIV protease inhibitor Drugs 0.000 title 1
CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims abstract description 10
230000008569 process Effects 0.000 claims abstract description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 105
150000001875 compounds Chemical class 0.000 claims description 66
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
239000000203 mixture Substances 0.000 claims description 23
239000003814 drug Substances 0.000 claims description 17
239000008194 pharmaceutical composition Substances 0.000 claims description 15
238000002425 crystallisation Methods 0.000 claims description 14
230000008025 crystallization Effects 0.000 claims description 14
229940079593 drug Drugs 0.000 claims description 14
108010010369 HIV Protease Proteins 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 4
230000000694 effects Effects 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 claims 1
239000000243 solution Substances 0.000 description 30
239000013078 crystal Substances 0.000 description 29
239000002904 solvent Substances 0.000 description 21
239000000523 sample Substances 0.000 description 16
239000012453 solvate Substances 0.000 description 14
239000000126 substance Substances 0.000 description 13
239000000047 product Substances 0.000 description 12
230000036571 hydration Effects 0.000 description 11
238000006703 hydration reaction Methods 0.000 description 11
239000002245 particle Substances 0.000 description 11
238000002474 experimental method Methods 0.000 description 10
230000003595 spectral effect Effects 0.000 description 9
238000003860 storage Methods 0.000 description 9
239000006185 dispersion Substances 0.000 description 8
238000001704 evaporation Methods 0.000 description 8
230000008020 evaporation Effects 0.000 description 8
238000002336 sorption--desorption measurement Methods 0.000 description 8
238000001914 filtration Methods 0.000 description 7
238000009472 formulation Methods 0.000 description 7
229940088679 drug related substance Drugs 0.000 description 6
238000001035 drying Methods 0.000 description 6
238000010438 heat treatment Methods 0.000 description 6
238000002329 infrared spectrum Methods 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
238000004090 dissolution Methods 0.000 description 5
239000012535 impurity Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
238000010899 nucleation Methods 0.000 description 5
238000001228 spectrum Methods 0.000 description 5
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
238000001237 Raman spectrum Methods 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
238000001816 cooling Methods 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
238000002844 melting Methods 0.000 description 4
239000000843 powder Substances 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
238000001179 sorption measurement Methods 0.000 description 4
208000016261 weight loss Diseases 0.000 description 4
230000004580 weight loss Effects 0.000 description 4
239000004698 Polyethylene Substances 0.000 description 3
239000008186 active pharmaceutical agent Substances 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000003795 desorption Methods 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
-1 hydroxyethylamino Chemical group 0.000 description 3
230000007774 longterm Effects 0.000 description 3
208000020442 loss of weight Diseases 0.000 description 3
239000012299 nitrogen atmosphere Substances 0.000 description 3
238000000634 powder X-ray diffraction Methods 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000007614 solvation Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000005292 vacuum distillation Methods 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
206010001513 AIDS related complex Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102000014961 Protein Precursors Human genes 0.000 description 2
230000009471 action Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
229940124522 antiretrovirals Drugs 0.000 description 2
239000003903 antiretrovirus agent Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000003750 conditioning effect Effects 0.000 description 2
238000000113 differential scanning calorimetry Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000011194 good manufacturing practice Methods 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000002547 new drug Substances 0.000 description 2
230000006911 nucleation Effects 0.000 description 2
239000005022 packaging material Substances 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000009738 saturating Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
238000000870 ultraviolet spectroscopy Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
101100328518 Caenorhabditis elegans cnt-1 gene Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
238000005079 FT-Raman Methods 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010078762 Protein Precursors Proteins 0.000 description 1
238000001069 Raman spectroscopy Methods 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
108700022715 Viral Proteases Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
238000012442 analytical experiment Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000004087 circulation Effects 0.000 description 1
239000003026 cod liver oil Substances 0.000 description 1
235000012716 cod liver oil Nutrition 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000001938 differential scanning calorimetry curve Methods 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004821 distillation Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000004508 fractional distillation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000001055 magnesium Nutrition 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000000155 melt Substances 0.000 description 1
239000013081 microcrystal Substances 0.000 description 1
238000003801 milling Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000002159 nanocrystal Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
238000012856 packing Methods 0.000 description 1
238000010951 particle size reduction Methods 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000012797 qualification Methods 0.000 description 1
239000010453 quartz Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000002002 slurry Substances 0.000 description 1
238000009331 sowing Methods 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000012430 stability testing Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002076 thermal analysis method Methods 0.000 description 1
238000002411 thermogravimetry Methods 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000009834 vaporization Methods 0.000 description 1
230000008016 vaporization Effects 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000006514 viral protein processing Effects 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Furan Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20045409A 2002-05-16 2004-12-10 Etanolat pseudopolymorfe former av en HIV-proteaseinhibitor, fremgangsmate ved fremstilling derav samt anvendelse derav NO331477B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02076929		2002-05-16
PCT/EP2003/050176 WO2003106461A2 (en)	2002-05-16	2003-05-16	Pseudopolymorphic forms of a hiv protease inhibitor

Publications (2)

Publication Number	Publication Date
NO20045409L NO20045409L (no)	2004-12-10
NO331477B1 true NO331477B1 (no)	2012-01-16

Family

ID=29724454

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20045409A NO331477B1 (no)	2002-05-16	2004-12-10	Etanolat pseudopolymorfe former av en HIV-proteaseinhibitor, fremgangsmate ved fremstilling derav samt anvendelse derav

Country Status (25)

Country	Link
US (8)	US7700645B2 (pl)
EP (4)	EP2314591B2 (pl)
JP (1)	JP4864320B2 (pl)
KR (2)	KR20100119906A (pl)
CN (1)	CN100475819C (pl)
AP (1)	AP2052A (pl)
AU (2)	AU2003271740B2 (pl)
BR (1)	BRPI0311176B8 (pl)
CA (1)	CA2485834C (pl)
CY (3)	CY1117928T1 (pl)
DK (3)	DK2767539T3 (pl)
EA (1)	EA007120B8 (pl)
ES (4)	ES2503551T5 (pl)
HR (1)	HRP20041061B1 (pl)
HU (1)	HUE034389T2 (pl)
IL (1)	IL165140A0 (pl)
LT (1)	LT2767539T (pl)
MX (1)	MXPA04011427A (pl)
NO (1)	NO331477B1 (pl)
NZ (1)	NZ536497A (pl)
PL (1)	PL215151B1 (pl)
PT (3)	PT2314591E (pl)
SI (3)	SI1567529T2 (pl)
WO (1)	WO2003106461A2 (pl)
ZA (1)	ZA200410154B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4776775B2 (ja)	1998-06-23	2011-09-21	アメリカ合衆国	Ｈｉｖ感染哺乳動物を治療するための医薬組成物
ES2503551T5 (es)	2002-05-16	2021-10-28	Janssen Sciences Ireland Unlimited Co	Formas pseudopolimórficas de un inhibidor de la proteasa de VIH
HRP20020614A2 (en) *	2002-07-22	2004-06-30	PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o.	Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
RS51073B (sr)	2003-12-23	2010-10-31	Tibotec Pharmaceuticals Ltd.	Proces za pripremanje (3r,3as,6ar)-heksahidrofuro│2,3-b│ furan-3-il (1s,2r)-3-││(4-aminofenil) sulfonil│(izobutil) amino │-1-benzil-2-hidroksipropilkarbamata
AU2006217922B2 (en)	2005-02-25	2012-04-05	Janssen Sciences Ireland Uc	Protease inhibitor precursor synthesis
ES2359949T3 (es) *	2006-11-09	2011-05-30	Tibotec Pharmaceuticals	Métodos para preparar hexhidrofuro(2,3-b)furan-3-ol.
AR073248A1 (es)	2008-09-01	2010-10-20	Tibotec Pharm Ltd	Proceso para la preparacion de (1s, 2r)-3- ((4-aminofenil) sulfonil) ( isobutil) amino)-1- bencil-2- hidroxipropilcarbamato de (3r, 3as,6ar)- hexahidrofuro-(2,3-b) furan-3- ilo (darunavir) y compuestos intermediarios utiles en dicho proceso.
US8921415B2 (en)	2009-01-29	2014-12-30	Mapi Pharma Ltd.	Polymorphs of darunavir
US20120035142A1 (en) *	2009-01-29	2012-02-09	Mapi Pharma Limited	Polymorphs of darunavir
WO2011048604A2 (en) *	2009-09-17	2011-04-28	Matrix Laboratories Limited	An improved process for the preparation of darunavir
WO2011051978A2 (en)	2009-10-30	2011-05-05	Lupin Limited	A novel process for preparation of darunavir and darunavir ethanolate of fine particle size
ES2546866T3 (es) *	2009-12-16	2015-09-29	Hetero Research Foundation	Polimorfos de darunavir
AU2010340799B2 (en) *	2010-01-05	2015-06-11	Cipla Limited	Darunavir polymorph and process for preparation thereof
EP2528923B1 (en)	2010-01-28	2014-07-30	Mapi Pharma Limited	Process for the preparation of darunavir and darunavir intermediates
EP2571355B1 (en)	2010-05-20	2016-09-07	Hetero Research Foundation	Crystalline hydrochloride salt of darunavir
WO2012107889A1 (en)	2011-02-10	2012-08-16	Ranbaxy Laboratories Limited	Process for the preparation of amorphous darunavir
SI2729130T1 (en)	2011-07-07	2018-03-30	Janssen Sciences Ireland Uc	Combined formulations of darunavir
WO2013114382A1 (en)	2011-12-05	2013-08-08	Mylan Laboratories Ltd	Crystalline darunavir
WO2013108105A2 (en) *	2012-01-18	2013-07-25	Aurobindo Pharma Limited	Novel solvates of darunavir
CN103509031B (zh) *	2012-06-20	2016-04-27	上海迪赛诺药业有限公司	制备达芦那韦无定形物的方法
ES2848216T3 (es) *	2012-07-24	2021-08-05	Laurus Labs Ltd	Un proceso para la preparación de Darunavir
WO2014068265A1 (en)	2012-10-29	2014-05-08	Cipla Limited	Antiviral phosphonate analogues and process for preparation thereof
US9346820B2 (en) *	2013-09-11	2016-05-24	Purdue Research Foundation	HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands
WO2016092525A1 (en) *	2014-12-12	2016-06-16	Lupin Limited	Darunavir n-propanol solvate and process for preparation thereof
WO2016092527A1 (en) *	2014-12-12	2016-06-16	Sun Pharmaceutical Industries Limited	A process for the preparation of dolutegravir
PL3271347T3 (pl) *	2015-03-19	2022-11-21	Mycovia Pharmaceuticals, Inc.	Związki przeciwgrzybicze i sposoby wytwarzania
US20190175511A1 (en)	2016-08-08	2019-06-13	Hetero Labs Limited	A Multi-Class Anti-Retroviral Composition
US11045423B2 (en)	2016-08-08	2021-06-29	Hetero Labs Limited	Anti-retroviral compositions
US10407438B2 (en)	2016-10-27	2019-09-10	Gilead Sciences, Inc.	Crystalline forms of darunavir
CN108727401A (zh) *	2017-04-20	2018-11-02	盐城迪赛诺制药有限公司	达鲁那韦新晶型及其制备方法和应用
CN109053753A (zh) *	2018-08-05	2018-12-21	浙江大学	一种制备达卢那韦二水合物晶型的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5413999A (en) *	1991-11-08	1995-05-09	Merck & Co., Inc.	HIV protease inhibitors useful for the treatment of AIDS
JPH05230044A (ja)	1992-02-21	1993-09-07	Hoechst Japan Ltd	ピレタニドの新規な結晶多形
US5968942A (en) *	1992-08-25	1999-10-19	G. D. Searle & Co.	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
AU7669794A (en) *	1993-08-24	1995-03-21	G.D. Searle & Co.	Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
CN1072215C (zh) *	1995-02-22	2001-10-03	赫彻斯特药品和化学品公司	无定形吡咯他尼、吡咯他尼多晶型物,其制备方法和用途
CO4940492A1 (es) *	1997-05-29	2000-07-24	Merck & Co Inc	Inhibidor de proteasa de vih
GB9712253D0 (en)	1997-06-13	1997-08-13	Glaxo Group Ltd	Antiviral compound
US6287693B1 (en) *	1998-02-25	2001-09-11	John Claude Savoir	Stable shaped particles of crystalline organic compounds
GB9805898D0 (en) *	1998-03-20	1998-05-13	Glaxo Group Ltd	Process for the sythesis of hiv protease inhibitors
GB9807354D0 (en)	1998-04-07	1998-06-03	Glaxo Group Ltd	Antiviral compound
JP4776775B2 (ja)	1998-06-23	2011-09-21	アメリカ合衆国	Ｈｉｖ感染哺乳動物を治療するための医薬組成物
WO1999067254A2 (en) *	1998-06-23	1999-12-29	The United States Of America Represented By The Secretary, Department Of Health And Human Services	Multi-drug resistant retroviral protease inhibitors and use thereof
WO2000029390A1 (en)	1998-11-19	2000-05-25	Du Pont Pharmaceuticals Company	Crystalline (-)-6- chloro-4- cyclopropylethynyl- 4-trifluoromethyl- 3,4-dihydro- 2(1h)-quinazolinone
EP1159278B1 (en)	1999-02-12	2005-11-30	Vertex Pharmaceuticals Incorporated	Inhibitors of aspartyl protease
ES2503551T5 (es)	2002-05-16	2021-10-28	Janssen Sciences Ireland Unlimited Co	Formas pseudopolimórficas de un inhibidor de la proteasa de VIH
AU2010340799B2 (en) *	2010-01-05	2015-06-11	Cipla Limited	Darunavir polymorph and process for preparation thereof

2003
- 2003-05-16 ES ES10180831T patent/ES2503551T5/es not_active Expired - Lifetime
- 2003-05-16 DK DK14168686.5T patent/DK2767539T3/en active
- 2003-05-16 AP AP2004003191A patent/AP2052A/xx active
- 2003-05-16 AU AU2003271740A patent/AU2003271740B2/en not_active Revoked
- 2003-05-16 LT LTEP14168686.5T patent/LT2767539T/lt unknown
- 2003-05-16 ES ES03753571T patent/ES2498370T5/es not_active Expired - Lifetime
- 2003-05-16 EP EP10180831.9A patent/EP2314591B2/en not_active Expired - Lifetime
- 2003-05-16 WO PCT/EP2003/050176 patent/WO2003106461A2/en not_active Ceased
- 2003-05-16 PT PT101808319T patent/PT2314591E/pt unknown
- 2003-05-16 EA EA200401503A patent/EA007120B8/ru unknown
- 2003-05-16 CN CNB038164590A patent/CN100475819C/zh not_active Expired - Lifetime
- 2003-05-16 CA CA002485834A patent/CA2485834C/en not_active Expired - Lifetime
- 2003-05-16 KR KR1020107024106A patent/KR20100119906A/ko not_active Ceased
- 2003-05-16 SI SI200332389T patent/SI1567529T2/sl unknown
- 2003-05-16 BR BRPI0311176A patent/BRPI0311176B8/pt active IP Right Grant
- 2003-05-16 DK DK03753571.3T patent/DK1567529T4/da active
- 2003-05-16 DK DK10180831.9T patent/DK2314591T4/da active
- 2003-05-16 PT PT37535713T patent/PT1567529E/pt unknown
- 2003-05-16 MX MXPA04011427A patent/MXPA04011427A/es active IP Right Grant
- 2003-05-16 ES ES14168686.5T patent/ES2638412T3/es not_active Expired - Lifetime
- 2003-05-16 SI SI200332383T patent/SI2314591T2/sl unknown
- 2003-05-16 ES ES16158480T patent/ES2728735T3/es not_active Expired - Lifetime
- 2003-05-16 EP EP16158480.0A patent/EP3045460B1/en not_active Expired - Lifetime
- 2003-05-16 EP EP14168686.5A patent/EP2767539B1/en not_active Expired - Lifetime
- 2003-05-16 EP EP03753571.3A patent/EP1567529B2/en not_active Expired - Lifetime
- 2003-05-16 NZ NZ536497A patent/NZ536497A/en not_active IP Right Cessation
- 2003-05-16 HR HRP20041061AA patent/HRP20041061B1/hr not_active IP Right Cessation
- 2003-05-16 PL PL374321A patent/PL215151B1/pl unknown
- 2003-05-16 SI SI200332545T patent/SI2767539T1/sl unknown
- 2003-05-16 JP JP2004513292A patent/JP4864320B2/ja not_active Expired - Lifetime
- 2003-05-16 US US10/514,352 patent/US7700645B2/en active Active
- 2003-05-16 HU HUE14168686A patent/HUE034389T2/en unknown
- 2003-05-16 KR KR1020047018426A patent/KR101128370B1/ko not_active Expired - Lifetime
- 2003-05-16 PT PT141686865T patent/PT2767539T/pt unknown
2004
- 2004-11-10 IL IL16514004A patent/IL165140A0/xx unknown
- 2004-12-10 NO NO20045409A patent/NO331477B1/no not_active IP Right Cessation
- 2004-12-15 ZA ZA2004/10154A patent/ZA200410154B/en unknown
2009
- 2009-08-06 US US12/536,807 patent/US8518987B2/en not_active Expired - Fee Related
2012
- 2012-07-03 AU AU2012205289A patent/AU2012205289A1/en active Pending
2013
- 2013-07-11 US US13/939,494 patent/US20130303790A1/en not_active Abandoned
2014
- 2014-02-19 US US14/183,712 patent/US20140171499A1/en not_active Abandoned
- 2014-09-17 CY CY20141100756T patent/CY1117928T1/el unknown
- 2014-09-17 CY CY20141100755T patent/CY1115665T1/el unknown
2015
- 2015-08-04 US US14/817,827 patent/US20150336980A1/en not_active Abandoned
2017
- 2017-05-22 US US15/600,932 patent/US10000504B2/en not_active Expired - Lifetime
- 2017-08-23 CY CY20171100896T patent/CY1119311T1/el unknown
2018
- 2018-05-16 US US15/980,993 patent/US10858369B2/en not_active Expired - Lifetime
2020
- 2020-10-30 US US17/085,096 patent/US20210179631A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUE034389T2 (en)	2018-02-28
NO20045409L (no)	2004-12-10
AP2052A (en)	2009-10-05
EP3045460A1 (en)	2016-07-20
EA200401503A1 (ru)	2005-06-30
CA2485834A1 (en)	2003-12-24
SI2314591T2 (sl)	2021-08-31
US20050250845A1 (en)	2005-11-10
US10858369B2 (en)	2020-12-08
US8518987B2 (en)	2013-08-27
CY1115665T1 (el)	2017-01-25
AU2003271740B2 (en)	2010-05-13
KR20100119906A (ko)	2010-11-11
EA007120B1 (ru)	2006-06-30
SI1567529T1 (sl)	2014-11-28
AP2004003191A0 (en)	2004-12-31
LT2767539T (lt)	2017-09-25
IL165140A0 (en)	2005-12-18
EP2767539A1 (en)	2014-08-20
WO2003106461A3 (en)	2004-05-13
EP2314591B1 (en)	2014-06-18
PT2767539T (pt)	2017-08-28
ES2498370T5 (es)	2021-11-24
CY1117928T1 (el)	2017-05-17
EP1567529B2 (en)	2021-02-24
EP1567529B1 (en)	2014-06-18
ES2498370T3 (es)	2014-09-24
HK1081969A1 (en)	2006-05-26
PT2314591E (pt)	2014-09-19
US20100204316A1 (en)	2010-08-12
AU2012205289A1 (en)	2012-08-09
HRP20041061A2 (en)	2006-07-31
BR0311176A (pt)	2005-03-15
CA2485834C (en)	2007-07-17
US20130303790A1 (en)	2013-11-14
SI2314591T1 (sl)	2014-11-28
DK1567529T4 (da)	2021-05-10
EP3045460B1 (en)	2019-04-17
DK1567529T3 (da)	2014-09-15
PL215151B1 (pl)	2013-10-31
EP1567529A2 (en)	2005-08-31
KR101128370B1 (ko)	2012-04-23
WO2003106461A2 (en)	2003-12-24
BRPI0311176B8 (pt)	2021-05-25
PL374321A1 (pl)	2005-10-17
NZ536497A (en)	2006-08-31
EP2314591A1 (en)	2011-04-27
KR20050008715A (ko)	2005-01-21
DK2314591T4 (da)	2021-05-10
BRPI0311176B1 (pt)	2019-08-20
DK2767539T3 (en)	2017-09-11
EP2314591B2 (en)	2021-02-24
ES2503551T5 (es)	2021-10-28
EA007120B8 (ru)	2012-03-30
US20150336980A1 (en)	2015-11-26
US10000504B2 (en)	2018-06-19
US20210179631A1 (en)	2021-06-17
ES2638412T3 (es)	2017-10-20
DK2314591T3 (da)	2014-09-22
US7700645B2 (en)	2010-04-20
CN1668623A (zh)	2005-09-14
PT1567529E (pt)	2014-09-09
CY1119311T1 (el)	2018-02-14
JP4864320B2 (ja)	2012-02-01
HRP20041061B1 (hr)	2015-02-27
US20180312517A1 (en)	2018-11-01
AU2003271740A1 (en)	2003-12-31
EP2767539B1 (en)	2017-07-12
SI2767539T1 (sl)	2017-10-30
US20140171499A1 (en)	2014-06-19
ZA200410154B (en)	2005-12-28
ES2728735T3 (es)	2019-10-28
SI1567529T2 (sl)	2021-08-31
CN100475819C (zh)	2009-04-08
US20170260196A1 (en)	2017-09-14
JP2005533068A (ja)	2005-11-04
ES2503551T3 (es)	2014-10-07
MXPA04011427A (es)	2005-02-17

Legal Events

Date	Code	Title	Description
2015-03-30	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: JANSSEN SCIENCES IRELAND UC, IE
2023-07-10	MK1K	Patent expired

Publication	Publication Date	Title
US20210179631A1 (en)	2021-06-17	Pseudopolymorphic Forms of a HIV Protease Inhibitor
US20120035142A1 (en)	2012-02-09	Polymorphs of darunavir
EP3655386A2 (en)	2020-05-27	New crystalline forms of vilanterol trifenatate and processes for their preparation
CA3166331A1 (en)	2021-09-23	Salts and crystalline forms of a taar1 agonist
KR20230117419A (ko)	2023-08-08	화합물의 결정형 및 이의 제조 방법과 적용
HK1081969B (en)	2014-09-05	Pseudopolymorphic forms of a hiv protease inhibitor
HK40074347A (en)	2022-12-30	Salts and crystalline forms of a taar1 agonist